| abstract |
The subject of the present invention is to provide a novel crystal form of compound with activating clotting factor X inhibition, which is useful for a pharmaceutical compsotion for prophylaxis and/or treatment of thrombotic and/or embolic diseases. According to the present invention, it provides a novel crystal form of N1-(5-chloropyridin-2-ly)-N2-((1S,2R, 4S)-4-[(dimethylamino)carbonyl]-2-{[(5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-yl)carbonyl]amino}cyclohexyl)ethanediamide p-tosilate hydrate, and a preparation method thereof. |